Please assess the completion status of the following clinical trial:

Trial Title: Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologic or cytologic diagnosis of non-small cell lung cancer (NSCLC), meeting 1 of the following staging criteria:~  * Stage IIIA disease, meeting all of the following criteria:~    * Mediastinal lymph node involvement~      * Greater than one mediastinal lymph node enlarged on CT scan, confirmed by positron emission tomography (PET) scan~   * Paralyzed left vocal cord with separate lung primary distinct from the aorto-pulmonary lymph nodes on the CT scan~ * Stage IIIB disease, meeting all of the following criteria:~    * N3 lymph node involvement~      * Enlarged N3 lymph nodes on CT scan confirmed by PET scan~        * Lymph node involvement may not extend to cervical lymph nodes other than supraclavicular lymph nodes~   * Right-sided primary tumor with left vocal cord paralysis~   * Evidence of tumor extension into the mediastinum and/or mediastinal structures by mediastinoscopy, bronchoscopy, or CT scan~   * No evidence of malignant pleural effusion unless effusion is only evident on CT scan~   * No more than 1 parenchymal lesions on the same or opposite sides of the lung~* No brain metastases by CT scan or MRI~PATIENT CHARACTERISTICS:~* SWOG performance status 0 or 1~* Platelet count ≥ 100,000/mm³~* Absolute neutrophil count ≥ 1,500/mm³~* Creatinine ≤ 1.5 times upper limit of normal (ULN)~* Creatinine clearance ≥ 45 mL/min~* Bilirubin normal~* Transaminases (SGOT and/or SGPT) ≤ 1.5 times ULN~* Alkaline phosphatase ≤ 2.5 times ULN~* Total lung volume (i.e., right and left lung minus the gross tumor volume) receiving greater than 20 Gy of radiation ≤ 40%~* FEV_1 ≥ 70% of predicted~* DLCO ≥ 50 mL/min~* No other concurrent malignancy~  * Prior malignancy allowed provided it is in clinical control and is not likely to impact clinical outcome in the opinion of the treating physician~* No peripheral neuropathy ≥ grade 2~* No serious medical illness, including, but not limited to, any of the following:~  * Uncontrolled congestive heart failure~ * Uncontrolled angina~ * Myocardial infarction~ * Cerebrovascular event within the past 6 months~ * History of chronic active hepatitis~ * History of HIV infection~ * Active bacterial infection~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Must be willing and able to take folic acid, cyanocobalamin (vitamin B12), or dexamethasone~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or radiotherapy for NSCLC~* No concurrent participation in another therapeutic investigational study~* Concurrent ibuprofen (400 mg four times daily) allowed during pemetrexed disodium administration provided the patient has normal renal function~* No concurrent aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs) 2 days before, during, and for 2 days after pemetrexed disodium administration~  * Patients on long-acting NSAIDs (e.g. naproxen sodium, diflunisal, nabumetone, or celecoxib) must be willing or able to discontinue usage 5 days prior to, during, and for 2 days after pemetrexed disodium administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Cisplatin, Docetaxel & Radiation Therapy (Type: EXPERIMENTAL): Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43; Docetaxel 75 mg/m2 on day 1 of each cycle; Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).